ArticleFrontiers in immunology2026
Huayu Wan enhances immune checkpoint inhibitor efficacy in triple-negative breast cancer by normalizing tumor vasculature and remodeling the tumor immune microenvironment.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Huayu Wan (HYW), a Traditional Chinese Medicine (TCM) formulation widely used in the clinical treatment of cancer, has demonstrated anti-tumor activity and augments chemotherapy efficacy by improving intratumoral drug delivery in non-small cell lung cancer. However, its efficacy and role in enhancing the response to immune checkpoint inhibitors (ICIs) for the treatment of triple-negative breast cancer (TNBC) remain unclear. Objective: To study the underlying mechanisms of HYW in enhancing the efficacy of ICIs for TNBC treatment. Materials and methods: In the 4T1 TNBC model, tumor growth, vascular structure/function, immune cell infiltration, angiogenic factors and effector cytokines were evaluated using ultrasound imaging, immunohistochemistry, immunofluorescence, and ELISA. HYW's effects on angiogenesis were validated via Results: TCGA data and network pharmacology identified VEGFA and the PI3K-Akt/HIF-1 signaling axis as key targets of HYW. HYW significantly enhanced ICIs efficacy, with a tumor inhibition rate of 36.55% (vs. 5.01% for ICIs alone). Mechanistically, HYW: Normalized tumor vasculature: Restored the balance between proangiogenic and antiangiogenic factors (reduced VEGFA/bFGF, increased TSP-1/PF4), enhanced pericyte coverage and improved vascular maturity, and enhanced intratumoral perfusion (ultrasound imaging). Alleviated hypoxia: Inhibited HIF-1α and reduced hypoxic regions (Hypoxyprobe staining). Remodeled the TME: Promoted CD8 Conclusion: HYW enhances ICIs efficacy in TNBC by normalizing tumor vasculature and remodeling the tumor immune microenvironment (TIME), which provides a novel rationale for combining TCM with ICIs to improve TNBC treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.